Intraoral administration of a T-cell epitope peptide induces immunological tolerance in Cry j 2-sensitized mice

Journal of Peptide Science

Volumn 13, Issue 8, 2007, Pages 499-503

  Yoshitomi, Tomomi ^a   Nakagami, Yasuhiro ^a   Hirahara, Kazuki ^a   Taniguchi, Yoshifumi ^b   Sakaguchi, Masahiro ^c   Yamashita, Makoto ^a  

^a DAIICHI SANKYO CO   (Japan)

^b HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Allergen; Cry j 2; Immunological tolerance; Sublingual immunotherapy; T cell epitope

Indexed keywords

ARGINYLALANYLGLUTAMYLVALYLSERYLTYROSYLVALYLHISTIDYLASPARAGYLGLYCYLALANYLLYSYLPHENYLALANINE; EPITOPE; P 2 246 259; PEPTIDE; PHOSPHATE BUFFERED SALINE; POLLEN ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; EX VIVO STUDY; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; IN VIVO STUDY; JAPANESE CEDAR; LYMPH NODE CELL; MITOSIS INHIBITION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; POLLEN ALLERGY; PRIORITY JOURNAL; SENSITIZATION;

ADMINISTRATION, ORAL; ALLERGENS; ANIMALS; CELL PROLIFERATION; EPITOPES, T-LYMPHOCYTE; IMMUNE TOLERANCE; IMMUNITY, MUCOSAL; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MOUTH MUCOSA; PEPTIDES; PLANT PROTEINS; RHINITIS, ALLERGIC, PERENNIAL;

ANIMALIA; CRYPTOMERIA JAPONICA; MUS;

EID: 34548245023     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.869     Document Type: Article

References (15)

1. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998; 53(Suppl. 44): 1-42.
2. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Imnumol. 2001; 108: S147-S334.
3. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60: 4-12.
4. Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J. Allergy Clin. Immunol. 2006; 117: 1021-1035.
5. Larche M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. 2005; 11: S69-S76.
6. Faria AM, Weiner HL. Oral tolerance. Immunol. Rev. 2005; 206: 232-259.
7. + regulatory T cells and suppresses delayed-type hypersensitivity reactions. Scand. J. Immunol. 2006; 64: 251-259.
8. Holt PG, Vines J, Britten D. Sublingual allergen administration. I. Selective suppression of IgE production in rats by high allergen doses. Clin. Allergy 1988; 18: 229-234.
9. Van Wilsem EJG, Brevé J, Savelkoul H, Claessen A, Scheper RJ, Kraal G. Oral tolerance is determined at the level of draining lymph nodes. Immunobiol. 1995; 194: 403-414.
10. Hirahara K, Saito S, Serizawa N, Sasaki R, Sakaguchi M, Inoue S, Taniguchi Y, Kaminogawa S, Shiraishi A. Oral administration of a dominant T-cell determinant peptide inhibits allergen-specific TH1 and TH2 cell responses in Cry j 2-primed mice. J. Allergy Clin. Immunol. 1998; 102:961-967.
11. Yoshitomi T, Hirahara K, Kawaguchi J, Serizawa N, Taniguchi Y, Saito S, Sakaguchi M, Inoue S, Shiraishi A. Three T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen antigens, retain their immunogenicity and tolerogenicity in a linked peptide. Immunology 2002; 107: 517-522.
12. Kawashima T, Taniai M, Usui M, Ando S, Kurimoto M, Matuhasi T. Antigenic analyses of sugi basic protein by monoclonal antibodies: II. Detection of immunoreactive fragments in enzyme-cleaved Cry j I. Int. Arch. Allergy Immunol. 1992; 98: 118-126.
13. Passalacqua G, Villa G, Altrinetti V, Falagiani P, Canonica GW, Marian G, Bagnasco M. Sublingual swallow or spit? Allergy 2001; 56: 578.
14. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61: 151-165.
15. Allam JP, Niederhagen B, Bücheler M, Appel T, Betten H, Bieber T, Bergé S, Novak N. Comparative analysis of nasal and oral mucosa dendritic cells. Allergy 2006; 61: 166-172.